Mapping of Local Renal Blood Flow with PET and H215O
Nathaniel M. Alpert, PhD;1,
Carlos A. Rabito, MD, PhD;1,
D. John A. Correia, PhD;1,
John W. Babich, PhD;1,
Bruce H. Littman, MD;2,
Ronald G. Tompkins, MD, DSc;3,4,5,
Nina T. Rubin, MD;6,
Robert H. Rubin, MD;1,3,7 and
Alan J. Fischman, MD, PhD1,6,7
1 Division of Nuclear Medicine, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts
2 Pfizer Global Research and Development, Groton, Connecticut
3 The Trauma Service, Massachusetts General Hospital, Boston, Massachusetts
4 Shriners Burns Institute, Harvard Medical School, Boston, Massachusetts
5 Departments of Radiology, Medicine, and Surgery, Harvard Medical School, Boston, Massachusetts
6 Renal Unit of the Medical Service, Massachusetts General Hospital, Boston, Massachusetts
7 Center of Experimental Pharmacology and Therapeutics, Harvard-MIT Division of Health Sciences and Technology, Boston, Massachusetts
View larger version (40K):
[in a new window]
|
FIGURE 1. Parametric maps of RBF for healthy subject (A) and for patient with moderate renal disease (B). Left column shows transverse cut through kidneys, whereas right column shows coronal cuts. Color bar provides quantitative scale in units of mL/min/cm3.
|
|
View larger version (15K):
[in a new window]
|
FIGURE 2. Comparison of hippuran clearance rates (mL/min) and mean RBF (mL/min/cm3) in control state. Solid line is linear regression. RBF = constant · Hippuran clearance rate.
|
|
View larger version (11K):
[in a new window]
|
FIGURE 3. Graph of RBF (mL/min/cm3) for healthy subjects ( ) and for patients with renal disease or kidney transplant (•) who were measured before treatment (RBF1) and 7 d after treatment (RBF2) with probenecid.
|
|
Copyright © 2002 by the Society of Nuclear Medicine.
